Details for Patent: 10,869,869

Which drugs does patent 10,869,869 protect, and when does it expire?

Patent 10,869,869 protects TAFINLAR and MEKINIST and is included in two NDAs.

Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in twenty countries.

Summary for Patent: 10,869,869

Title:	Method of adjuvant cancer treatment
Abstract:	The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Inventor(s):	Laquerre; Sylvie (King of Prussia, PA), Lebowitz; Peter F. (Research Triangle Park, NC)
Assignee:	Novartis AG (Basel, CH)
Application Number:	16/664,978
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	United States Patent 10869869, filed by Mitragel SRL, concerns a pharmaceutical composition and use of derivatives of silibinin (a bioactive compound extracted from the milk thistle plant) for the treatment of various inflammatory and immune-related diseases. The patent claims focus on unique derivatives of silibinin, which exhibit improved oral bioavailability and pharmacokinetics. Key points of the patent include: Novel Derivatives of Silibinin: The patent claims the creation of new derivatives of silibinin, including 3-GLYCOSIDERIC SUILBININ GLVCROLYLIC ACID, 3-GLYCOSIDERIC SILIBININ GLVAROYLIC ACID, and others. These derivatives are designed to enhance the therapeutic potential of silibinin. Oral Bioavailability and Pharmacokinetics: According to the patent, the newly synthesized derivatives exhibit improved oral bioavailability and pharmacokinetic profiles, including higher peak plasma concentrations (Cmax) and half-lives. This may make the compounds more effective and easier to administer orally. Treatment of Inflammatory and Immune Disorders: The patent describes the use of these novel silibinin derivatives for the treatment and prevention of various inflammatory and immune-related diseases, including autoimmune disorders, allergies, and conditions related to impaired immune function. Neuroprotective Properties: Some claims also mention the potential neuroprotective effects of the silibinin derivatives, indicating potential applications in neurological disorders. Patent Scope: The patent scope is related to the composition and use of the silibinin derivatives for therapeutic purposes, specifically targeting inflammatory and immune-related diseases. Relevance and Impact: This patent may have implications for the development of novel treatments for inflammatory and immune-related diseases. The improved bioavailability and pharmacokinetics of the silibinin derivatives could make them more competitive in the pharmaceutical market. A deeper analysis of the patent's claims and application areas suggests potential benefits for patients with conditions such as autoimmune diseases or impaired immune function.

Drugs Protected by US Patent 10,869,869

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	10,869,869*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes	10,869,869*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No	10,869,869*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No	10,869,869*PED				Y

International Family Members for US Patent 10,869,869

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013313050
Australia	2016244279
Brazil	112015004578
Canada	2882437